These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38672254)

  • 1. Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes.
    Gupta M; Anjari M; Brandner S; Fersht N; Wilson E; Thust S; Kosmin M
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
    Keric N; Krenzlin H; Kalasauskas D; Freyschlag CF; Schnell O; Misch M; von der Brelie C; Gempt J; Krigers A; Wagner A; Lange F; Mielke D; Sommer C; Brockmann MA; Meyer B; Rohde V; Vajkoczy P; Beck J; Thomé C; Ringel F
    J Neurooncol; 2024 Mar; 167(1):133-144. PubMed ID: 38326661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance spectroscopic correlates of progression free and overall survival in "glioblastoma, IDH-wildtype, WHO grade-4".
    Sacli-Bilmez B; Danyeli AE; Yakicier MC; Aras FK; Pamir MN; Özduman K; Dinçer A; Ozturk-Isik E
    Front Neurosci; 2023; 17():1149292. PubMed ID: 37457011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
    Ma S; Rudra S; Campian JL; Dahiya S; Dunn GP; Johanns T; Goldstein M; Kim AH; Huang J
    Neurooncol Adv; 2020; 2(1):vdaa126. PubMed ID: 33235995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
    Tesileanu CMS; Sanson M; Wick W; Brandes AA; Clement PM; Erridge SC; Vogelbaum MA; Nowak AK; Baurain JF; Mason WP; Wheeler H; Chinot OL; Gill S; Griffin M; Rogers L; Taal W; Rudà R; Weller M; McBain C; van Linde ME; Aldape K; Jenkins RB; Kros JM; Wesseling P; von Deimling A; Hoogstrate Y; de Heer I; Atmodimedjo PN; Dubbink HJ; Brouwer RWW; van IJcken WFJ; Cheung KJ; Golfinopoulos V; Baumert BG; Gorlia T; French PJ; van den Bent MJ
    Clin Cancer Res; 2022 Jun; 28(12):2527-2535. PubMed ID: 35275197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.
    Kumari K; Dandapath I; Singh J; Rai HIS; Kaur K; Jha P; Malik N; Chosdol K; Mallick S; Garg A; Suri A; Sharma MC; Sarkar C; Suri V
    Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):410-417. PubMed ID: 35708480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and radiographic characteristics of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma: a single institution review.
    Grogan D; Bray DP; Cosgrove M; Boucher A; Erwood A; Linder DF; Mendoza P; Morales B; Pradilla G; Nduom EK; Neill S; Olson JJ; Hoang KB
    J Neurooncol; 2022 Mar; 157(1):187-195. PubMed ID: 35212929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis.
    Hasselblatt M; Jaber M; Reuss D; Grauer O; Bibo A; Terwey S; Schick U; Ebel H; Niederstadt T; Stummer W; von Deimling A; Paulus W
    J Neuropathol Exp Neurol; 2018 Jun; 77(6):422-425. PubMed ID: 29444314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study.
    Ramos-Fresnedo A; Pullen MW; Perez-Vega C; Domingo RA; Akinduro OO; Almeida JP; Suarez-Meade P; Marenco-Hillembrand L; Jentoft ME; Bendok BR; Trifiletti DM; Chaichana KL; Porter AB; Quiñones-Hinojosa A; Burns TC; Kizilbash SH; Middlebrooks EH; Sherman WJ
    J Neurooncol; 2022 Mar; 157(1):177-185. PubMed ID: 35175545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
    J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
    J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Characterization of "True" Low-Grade IDH-Wildtype Astrocytomas.
    Richardson TE; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):431-435. PubMed ID: 33829259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.